Navigation Links
Market for Niche Blockbusters Promises an Attractive Future for Large Pharmaceutical Companies, Indicates Frost & Sullivan
Date:2/25/2009

LONDON, Feb. 25 /PRNewswire/ -- The patent expiry of blockbuster molecules has resulted in large pharmaceutical companies confronting intense competition from generics. CEOs have had to rethink strategies and devise alternative approaches to maintain the growth of their organisation and satisfy stakeholders.

(Logo: http://www.newscom.com/cgi-bin/prnh/20081117/FSLOGO)

A focus on the market for niche blockbuster drugs represents a potential strategy that can be pursued by large pharmaceutical companies. For instance, there has been strong growth in the orphan diseases market, due to various incentives and benefits provided by governments. In the European Union (EU), the emphasis is on orphan diseases, as it is a promising, emergent market that offers the prospect of assured return on investment (ROI).

New analysis from Frost & Sullivan (http://www.pharma.frost.com), European Orphan Diseases Market, finds that the market earned revenues of $16.48 billion in 2008 and estimates this to reach $27.09 billion in 2015. This study thoroughly examines the following markets: orphan diseases, Gaucher's Disease and Pulmonary Arterial Hypertension (PAH) markets in Europe.

If you are interested in a virtual brochure, which provides a brief synopsis of the research and a table of contents, then send an e-mail to Katja Feick, Corporate Communications, at katja.feick@frost.com, with your full name, company name, title, telephone number, company e-mail address, company website, city, state and country. Upon receipt of the above information, a brief brochure will be sent to you by e-mail.

As leading pharmaceutical companies are facing increasing competition because of impending patent expiries of blockbuster drugs, a number of companies are pursuing merger and acquisition of small biotechnology companies.

"The market is set to witness major consolidation due to mergers and acquisitions among big pharmaceuticals and small biotech companies," notes Frost & Sullivan Programme Leader Shabeer Hussain. "The lack of adequate investment to support the development of newer therapies and technologies has been a major challenge for small biotechnology companies, resulting in their tilt towards merging with larger companies."

The European orphan diseases market grapples with numerous challenges. Of these, the most serious are the lack of awareness, poor diagnosis and limited accessibility of orphan drugs.

"There are diverse policies among EU member countries with regard to the accessibility of orphan drugs," remarks Hussain. "This is retarding market expansion."

EU-wide harmonisation in the context of accessibility processes and price policies will reduce delays in the availability of orphan drugs. EU-wide co-ordination will also help in streamlining the regulatory process governing these drugs.

EU healthcare ministers should encourage frequent discussions with patients, patient support groups and industry representatives to ensure a transparent and rapid approval process for orphan drugs.

European Orphan Diseases Market is part of the Pharmaceuticals & Biotechnology Growth Partnership Service programme, which also includes research in the following markets: European Vaccines Market, European Biosimilars Market and Drug Approval Process in Europe - An Outlook. All research included in subscriptions provide detailed market opportunities and industry trends that have been evaluated following extensive interviews with market participants. Interviews with the press are available.

Frost & Sullivan has expanded its flagship Global Congress on Corporate Growth - GIL Global - into several major cities around the world including London. For the first time ever in Europe, Frost & Sullivan will be hosting the Growth, Innovation and Leadership Congress 'GIL 2009: Europe' on 19-20 May, at the Sofitel St James in London. GIL Global is the industry's only event designed to support senior executives in their efforts to achieve sustainable, top-line growth. To register, obtain a programme agenda, explore sponsorship opportunities, or attend as a member of the media for GIL 2009: Europe, please contact Katja Feick, Corporate Communications Europe, at katja.feick@frost.com. One-on-One interviews with Frost & Sullivan senior growth consultants are also being scheduled. For more information you can also visit www.frost.com/giluk

Frost & Sullivan, the Growth Partnership Company, enables clients to accelerate growth and achieve best in class positions in growth, innovation and leadership. The company's Growth Partnership Service provides the CEO and the CEO's Growth Team with disciplined research and best practice models to drive the generation, evaluation and implementation of powerful growth strategies. Frost & Sullivan leverages over 45 years of experience in partnering with Global 1000 companies, emerging businesses and the investment community from 31 offices on six continents. To join our Growth Partnership, please visit http://www.frost.com.

European Orphan Diseases Market

M34D

    Contact:
    Katja Feick
    Corporate Communications - Europe
    P: +49 (0) 69 7703343
    E: katja.feick@frost.com
   http://www.frost.com


'/>"/>
SOURCE Frost & Sullivan
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Zyloprim(R)
2. Ranbaxy Receives Tentative Approval to Manufacture and Market Galantamine Tablets on an Exclusive Basis
3. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Adipex-P(R)
4. Omnicom Acquires Leading Healthcare Marketing Communications Firm in China
5. Sodexho, Inc. Announces Patrick E. Connolly as Market President & COO
6. Expanding Prevalent Population Will Drive Dramatic Growth for the Asthma Drug Market in China
7. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Coreg(R)
8. Paramount Acquisition Corp. Announces Chem Rx Expansion into Albany, New York Market
9. Innocoll Agrees the Sale of its CollaRx(R) GENTAMICIN SURGICAL IMPLANT and European Sales and Marketing Infrastructure to EUSA Pharma
10. Ranbaxy Gains Approval to Manufacture and Market Carvedilol Tablets in the U.S. Market
11. Bioniche Receives $2 Million Government Grant For Market Development Related to its E. coli O157:H7 Cattle Vaccine
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2017)... ... ... The American Board of Family Medicine's (ABFM) Board of Directors has selected Warren ... James C. Puffer upon his retirement. Dr. Newton will serve in the position of ... end of 2018. Upon assuming the role of President and CEO on January 1, ...
(Date:10/13/2017)... ... 13, 2017 , ... Apple Rehab Shelton Lakes , which specializes in ... the facility as part of a disaster drill on October 3rd. , Apple Rehab ... City Emergency Manager, as well as the Connecticut Long Term Care Mutual Aid ...
(Date:10/13/2017)... Texas (PRWEB) , ... October 13, 2017 , ... Yisrayl ... this week that explains one of the most popular and least understood books in ... like cryptic and puzzling descriptions that have baffled scholars for centuries. Many have tossed ...
(Date:10/12/2017)... ... 2017 , ... First Healthcare Compliance (FHC), an industry leader ... range of technology and learning solutions at the 68th Annual American Healthcare Association ... held October 14–18, 2017 at the Mandalay Bay Resort in Las Vegas, Nevada. ...
(Date:10/12/2017)... (PRWEB) , ... October 12, 2017 , ... The American ... Excellence to Carol Friedman, PhD, FACMI, during the Opening Session of AMIA’s Annual Symposium ... 8. , In honor of Morris F. Collen, a pioneer in the field of ...
Breaking Medicine News(10 mins):
(Date:10/11/2017)...  BioPharmX Corporation (NYSE MKT: BPMX) researchers were part ... way to use nonlinear optical imaging to confirm the ... A presentation ... how researchers from BioPharmX and the Wellman Center for ... suite of imaging techniques in what is called "Pharmacokinetic ...
(Date:10/10/2017)...  NDS received FDA 510(k) clearance in May 2017 for its ... specifically designed for endoscopy environments. An innovative secondary monitor solution, ZeroWire ... to support the improvement of patient outcomes, procedural efficiency, and the ... ... ...
(Date:10/4/2017)... 4, 2017  South Korean-based healthcare product Development Company ... "cprCUBE" on Kickstarter. The device will educate the user ... with better efficiency compared to the dated and pricey ... on efficacy of the compression for a more informed ... goal to raise $5,000. ...
Breaking Medicine Technology: